Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

Launched by MEDICAL UNIVERSITY OF SOUTH CAROLINA · Oct 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with chronic pancreatitis who are scheduled to undergo a surgical procedure called total pancreatectomy with islet autotransplantation (TP-IAT). The researchers want to find out if adding a type of stem cell, called mesenchymal stem cells (MSCs), to the standard treatment can improve outcomes for patients. Participants will be randomly assigned to receive either the MSC treatment or the standard care, and they will be followed for one year after the transplant to see how they are doing.

To be eligible for this trial, patients must be at least 18 years old, have a diagnosis of chronic pancreatitis, and be scheduled for the TP-IAT surgery. It's important that they also have diabetes with a specific blood sugar level, but they cannot be on any immunosuppressive medications or have certain liver issues. Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. This trial is currently recruiting participants of all genders between the ages of 65 to 74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of CP and scheduled for TP-IAT;
• • ≥18 years old;
• • Diabetes with HbA1c \<12%.
• Exclusion Criteria:
• • Patients who are under immunosuppression;
• • Pregnant and breastfeeding women.
• • Patients who have liver damage based on ALT, AST, and total bilirubin levels (\>3 times normal levels);